entertainment -WSS

entertainment

author：explore 2025-09-30 18:21:07 - browse：13

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： BMS, looking to build heart drug business, turns to AI for diagnosis

WSS

Bird flu researchers hone in on Finland’s mink farms

Be careful with at

Baby aspirin cuts fat buildup in liver disease patients, in small study

SCOTUS questions limit to govt efforts to fight misinformation

Be careful with at

Asbestos, a deadly carcinogen, banned by EPA

explore

entertainment

knowledge

Apple is now the first public company to be valued at $3 trillion

Methadone treatment changes are coming. Do they go far enough?

23andMe had bad news about my health. I wish a person had delivered it

Treatments for cramps don't cut it. Why aren't there better options?

How one medical school became remarkably diverse

YouTube cracks down on misinformation on cancer treatment

Drug repurposing or repositioning? The language matters

Creating egg and sperm cells from stem cells raises ethical issues

In Memoriam: Notable people who died in 2023

Patients, digital health players weigh in on FTC's data privacy plan

Wikipedia

Virtual Event: March of the Biosimilars

Gene editing the human germline: What are the risks?

UnitedHealth increases loan offers after Change Healthcare outage

Creating egg and sperm cells from stem cells raises ethical issues

Health AI: on the border between health care and tech

BMS, looking to build heart drug business, turns to AI for diagnosis

explore

focus

explore

hotspot